Last reviewed · How we verify
Phentolamine Mesylate (NV-101)
Phentolamine Mesylate (NV-101) is a alpha-adrenergic receptor antagonist Small molecule drug developed by Novalar Pharmaceuticals, Inc.. It is currently in Phase 3 development for Hypertension, Pheochromocytoma.
Phentolamine mesylate is an alpha-adrenergic receptor antagonist that works by blocking the action of norepinephrine, a neurotransmitter that can cause blood vessels to constrict.
Phentolamine mesylate is an alpha-adrenergic receptor antagonist that works by blocking the action of norepinephrine, a neurotransmitter that can cause blood vessels to constrict. Used for Hypertension, Pheochromocytoma.
At a glance
| Generic name | Phentolamine Mesylate (NV-101) |
|---|---|
| Sponsor | Novalar Pharmaceuticals, Inc. |
| Drug class | alpha-adrenergic receptor antagonist |
| Target | alpha-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By blocking alpha-adrenergic receptors, phentolamine mesylate causes blood vessels to dilate, which can help to reduce blood pressure and alleviate symptoms of pheochromocytoma. This mechanism of action is specific to the treatment of hypertension and pheochromocytoma.
Approved indications
- Hypertension
- Pheochromocytoma
Common side effects
- Hypotension
- Tachycardia
- Dizziness
Key clinical trials
- Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures (PHASE2)
- Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures (PHASE3)
- Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures (PHASE3)
- Safety and Efficacy Study of NV-101 in Dental Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phentolamine Mesylate (NV-101) CI brief — competitive landscape report
- Phentolamine Mesylate (NV-101) updates RSS · CI watch RSS
- Novalar Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Phentolamine Mesylate (NV-101)
What is Phentolamine Mesylate (NV-101)?
How does Phentolamine Mesylate (NV-101) work?
What is Phentolamine Mesylate (NV-101) used for?
Who makes Phentolamine Mesylate (NV-101)?
What drug class is Phentolamine Mesylate (NV-101) in?
What development phase is Phentolamine Mesylate (NV-101) in?
What are the side effects of Phentolamine Mesylate (NV-101)?
What does Phentolamine Mesylate (NV-101) target?
Related
- Drug class: All alpha-adrenergic receptor antagonist drugs
- Target: All drugs targeting alpha-adrenergic receptor
- Manufacturer: Novalar Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Pheochromocytoma
- Compare: Phentolamine Mesylate (NV-101) vs similar drugs
- Pricing: Phentolamine Mesylate (NV-101) cost, discount & access